• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by MetLife Inc. (Amendment)

    5/4/23 5:02:56 PM ET
    $MET
    Life Insurance
    Finance
    Get the next $MET alert in real time by email
    SC 13D/A 1 d502214dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    AMENDMENT NO. 93 TO

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

     

     

    MetLife, Inc.

    (Name of Issuer)

    Common Stock, par value $.01 per share

    (Title of Class of Securities)

    59156R108

    (CUSIP Number)

    Stephen W. Gauster

    Executive Vice President and General Counsel

    MetLife, Inc.

    200 Park Avenue

    New York, NY 10166-0188

    (212) 578-9500

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 4, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐.

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

      •  

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    SCHEDULE 13D

     

    CUSIP No. 59156R108   Page 2 of 9 Pages  

     

      (1)   

    Names of Reporting Persons                                    Board of Directors of MetLife, Inc., as an entity

     

    I.R.S. Identification

    Nos. of Above Persons                                                     Not applicable

      (2)  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds

     

        Not Applicable. See Item 4.

      (5)  

    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

        ☐

      (6)  

    Citizenship or Place of Organization

     

        U.S.A.

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

         (7)    

    Sole Voting Power

     

        0

         (8)   

    Shared Voting Power

     

    121,521,424*

         (9)   

    Sole Dispositive Power

     

        0

       (10)   

    Shared Dispositive Power

     

        0

    (11)  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    121,521,424*

    (12)  

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

        ☐

    (13)  

    Percent of Class Represented by Amount in Row 11

     

    15.9%

    (14)  

    Type of Reporting Person

     

        IC

     

    *

    Unless otherwise indicated, all information relating to beneficial ownership of the Shares by the Reporting Persons is as of April 28, 2023.


    SCHEDULE 13D

     

    CUSIP No. 59156R108   Page 3 of 9 Pages

    Items 4 and 5 are amended and restated as set forth below:

    ITEM 4. PURPOSE OF TRANSACTION.

    The Board of Directors (the “Board”) is reporting beneficial ownership of 121,521,424 shares of Common Stock (the “Shares”) held by the MetLife Policyholder Trust (the “Trust”) under the Plan of Reorganization, dated September 28, 1999, as amended (the “Plan”), of Metropolitan Life Insurance Company (“MetLife”).

    On April 7, 2000, 494,466,664 Shares were issued to the Trust pursuant to Section 5.2(d) of the Plan, a copy of which is attached as an exhibit to this statement. No consideration has been separately provided therefor by any member of the Board, except for Shares allocated to such member pursuant to the Plan. Since April 7, 2000, transactions by Beneficiaries (i) under the Purchase and Sale Program provided for by the Trust Agreement (as defined below), (ii) pursuant to the Issuer’s split-off of Reinsurance Group of America, Incorporated, in September 2008, and (iii) to withdraw Shares from the Trust, as well as escheatment of unclaimed Shares, have resulted in a decrease in the number of Shares held by the Trust from 494,466,664
    to 121,521,424 (as adjusted to reflect refinements in the calculation of the number of Shares issued to the Trust under the Plan).

    Under the Plan and the MetLife Policyholder Trust Agreement, dated as of November 3, 1999 (as amended, the “Trust Agreement”), by and among MetLife, the Issuer, Wilmington Trust Company (the “Trustee”) and ChaseMellon Shareholder Services, L.L.C., as custodian (now known as Computershare Inc., the “Custodian”), a copy of which is attached as an exhibit to this statement, certain eligible policyholders of MetLife (“Trust Eligible Policyholders”) have been allocated a number of interests in the Trust (“Trust Interests”) equal to the number of shares of Common Stock allocated to the Trust Eligible Policyholders in accordance with the Plan. The assets of the Trust principally are the Shares issued to the Trust for the benefit of the Trust Eligible Policyholders and permitted transferees (collectively, the “Beneficiaries”). The Shares are held in the name of the Trustee, on behalf of the Trust, which has legal title over the Shares. The Beneficiaries do not have legal title to any part of the assets of the Trust. The Trust Interests represent undivided fractional interests in the Shares and other assets of the Trust beneficially owned by a Trust Beneficiary through the Custodian.

    The Trust Agreement provides the Trustee with directions as to the manner in which to vote, assent or consent the Shares at all times during the term of the Trust. On all matters brought for a vote before the stockholders of the Issuer, with the exception of a Beneficiary Consent Matter (as defined below), the Trustee will vote in accordance with the recommendation given by the Board of the Issuer to its stockholders or, if no such recommendation is given, as directed by the Board. On all Beneficiary Consent Matters, the Trustee will vote all of the Shares in favor of, in opposition to or abstain from the matter in the same ratio as the Trust Interests of the Beneficiaries that returned voting instructions to the Trustee indicated preferences for voting in favor of, in opposition to or abstaining from such matter. The Trust Agreement also contains provisions allowing Beneficiaries to instruct the Custodian to withdraw their allocated Trust Shares to participate in any tender or exchange offer for the Common Stock and to make any cash or share election, or perfect any dissenter’s rights, in connection with a merger of the Issuer.


    SCHEDULE 13D

     

    CUSIP No. 59156R108   Page 4 of 9 Pages

    A “Beneficiary Consent Matter” is:

     

      (i)

    a contested election of directors or, subject to certain conditions, the removal of a director,

     

      (ii)

    a merger or consolidation, a sale, lease or exchange of all or substantially all of the assets or a recapitalization or dissolution of the Issuer, if it requires a vote of stockholders under applicable Delaware law,

     

      (iii)

    any transaction that would result in an exchange or conversion of the Shares for cash, securities or other property,

     

      (iv)

    issuances of Common Stock prior to the first anniversary of the effective date of the Plan (the “Effective Date”) at a price materially below the prevailing market price, if a vote is required to approve the issuance under Delaware law, other than issuances in an underwritten public offering or pursuant to an employee benefit plan,

     

      (v)

    before the first anniversary of the Effective Date, any matter that requires approval by a vote of more than a majority of the outstanding stock of the Issuer entitled to vote thereon under Delaware law or the certificate of incorporation or the by-laws of the Issuer, and any amendment to the certificate of incorporation or by-laws of the Issuer that is submitted to a vote of stockholders for approval, and

     

      (vi)

    proposals submitted to stockholders requiring the Board to amend the Issuer’s stockholder rights plan, or redeem rights under that plan, other than a proposal with respect to which the Issuer has received advice of nationally-recognized legal counsel to the effect that the proposal is not a proper subject for stockholder action under Delaware law. The Issuer does not currently have a stockholder rights plan.

    The Trust Agreement contains provisions enabling the Beneficiaries to withdraw the Shares allocated to them under the Plan and the Trust Agreement for resale or otherwise and to receive dividends on such Shares.


    SCHEDULE 13D

     

    CUSIP No. 59156R108   Page 5 of 9 Pages

    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

     

    (a)

    As an entity, the Board of the Issuer beneficially owns 121,521,424 shares, or 15.9% of the Issuer’s outstanding Common Stock. The Board of the Issuer is deemed to beneficially own the shares of Common Stock held by the Trust because the Board will direct the voting of these shares on certain matters submitted to a vote of stockholders. See Item 4.

     

    (b)

    As an entity, the Board of the Issuer has shared voting power with respect to 121,521,424 shares of Common Stock.

     

    (c)

    There were no transactions in the class of securities reported on that were effected by the Reporting Persons since February 14, 2023 other than transactions described in Item 4 which resulted in a decrease in the number of shares of Common Stock held by the Trust from 122,923,807 to 121,521,424.

     

    (d)

    The Beneficiaries of the Trust have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares allocated to them under the Plan and the Trust Agreement. See Item 4.

    ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

    Exhibit 99.1 Joint Filing Agreement under Rule 13d-1(k)(1)

    Exhibit 99.2 Power of Attorney


    SCHEDULE 13D

     

    CUSIP No. 59156R108   Page 6 of 9 Pages

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

    Dated: May 4, 2023

     

    *

    Cheryl W. Grisé

        

    *

    Carlos M. Gutierrez

        

    *

    Carla A. Harris

        

    *

    Gerald L. Hassell

        

    *

    David L. Herzog

        

    *

    R. Glenn Hubbard

        

    *

    Jeh C. Johnson

        

    *

    Edward J. Kelly, III

        

    *

    William E. Kennard

        

    *

    Michel A. Khalaf

        

    *

    Catherine R. Kinney

        

    *

    Diana L. McKenzie

        

    *

    Denise M. Morrison

        

    *

    Mark A. Weinberger

        


    SCHEDULE 13D

     

    CUSIP No. 59156R108   Page 7 of 9 Pages

     

                       * By    /s/ Stephen W. Gauster
        Stephen W. Gauster
        Attorney-in-fact
    Get the next $MET alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MET

    DatePrice TargetRatingAnalyst
    1/23/2025$97.00Market Perform
    BMO Capital Markets
    10/9/2024$97.00Buy
    TD Cowen
    9/5/2024$91.00Overweight
    Barclays
    1/8/2024$80.00Neutral → Buy
    Goldman
    11/17/2023$71.00Overweight
    Barclays
    10/5/2023$71.00Hold
    Deutsche Bank
    9/14/2023$58.00 → $72.00Hold → Buy
    Jefferies
    1/9/2023$80.00 → $78.00Buy → Neutral
    Goldman
    More analyst ratings

    $MET
    Leadership Updates

    Live Leadership Updates

    See more
    • MetLife Investment Management Agrees to Acquire Traditional Fixed Income and Equity Portfolio Management Teams Managing $6 Billion From Mesirow

      Acquisition includes high yield, strategic fixed income and small-cap equity teams MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE:MET), today announced that it has reached a definitive agreement to acquire three investment teams and assets managed by Mesirow, an independent, employee-owned financial services firm. MIM is acquiring the high yield and bank loan, strategic fixed income and small-cap equity teams and certain related investment products. Under the terms of the transaction, about $6 billion of assets managed by the acquired teams will transfer to MIM, subject to customary approvals and consents. The acquisition is consi

      1/8/25 8:30:00 AM ET
      $MET
      Life Insurance
      Finance
    • MetLife Investment Management Names Kerry O'Brien Global Head of Insurance Asset Management and Liability Solutions

      MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE:MET), today announced that it has appointed Kerry O'Brien as global head of Insurance Asset Management and Liability Solutions. She will be responsible for the execution of investment strategies for the MetLife general account, helping drive growth in MIM's third-party insurance client channel as well as working with teams to drive liability solutions across other client segments. O'Brien will lead a team with an insurance investing heritage of nearly 150 years and an active role in managing MetLife's $414.1 billion general account as well as assets for third-party insurance clients. Sh

      12/2/24 8:30:00 AM ET
      $MET
      Life Insurance
      Finance
    • MetLife Worldwide Benefits and GeoBlue® to Offer Joint Solution

      Combining the medical and ancillary strengths of two leading global carriers into a single solution -- Globaline™ MetLife and GeoBlue, the international solution for the Blue Cross® Blue Shield® companies, announced today they will offer a full suite of expatriate benefit products in a best-in-class single solution, Globaline™. Globaline™ brings together health coverage and services from GeoBlue – including medical, dental, vision, prescription, wellness, international employee assistance program and political and natural disaster assistance – and life, accidental death & dismemberment and long term disability coverage from MetLife Worldwide Benefits, including value-added services, such

      6/25/24 9:00:00 AM ET
      $MET
      Life Insurance
      Finance

    $MET
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BMO Capital Markets initiated coverage on MetLife with a new price target

      BMO Capital Markets initiated coverage of MetLife with a rating of Market Perform and set a new price target of $97.00

      1/23/25 7:50:09 AM ET
      $MET
      Life Insurance
      Finance
    • TD Cowen initiated coverage on MetLife with a new price target

      TD Cowen initiated coverage of MetLife with a rating of Buy and set a new price target of $97.00

      10/9/24 7:52:22 AM ET
      $MET
      Life Insurance
      Finance
    • Barclays initiated coverage on MetLife with a new price target

      Barclays initiated coverage of MetLife with a rating of Overweight and set a new price target of $91.00

      9/5/24 8:14:53 AM ET
      $MET
      Life Insurance
      Finance

    $MET
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by MetLife Inc.

      SC 13D/A - METLIFE INC (0001099219) (Subject)

      11/1/24 5:05:26 PM ET
      $MET
      Life Insurance
      Finance
    • Amendment: SEC Form SC 13D/A filed by MetLife Inc.

      SC 13D/A - METLIFE INC (0001099219) (Subject)

      8/1/24 4:38:49 PM ET
      $MET
      Life Insurance
      Finance
    • SEC Form SC 13D/A filed by MetLife Inc. (Amendment)

      SC 13D/A - METLIFE INC (0001099219) (Subject)

      5/2/24 5:34:57 PM ET
      $MET
      Life Insurance
      Finance

    $MET
    SEC Filings

    See more
    • SEC Form 10-Q filed by MetLife Inc.

      10-Q - METLIFE INC (0001099219) (Filer)

      5/1/25 5:21:25 PM ET
      $MET
      Life Insurance
      Finance
    • SEC Form 8-K filed by MetLife Inc.

      8-K - METLIFE INC (0001099219) (Filer)

      4/30/25 4:44:27 PM ET
      $MET
      Life Insurance
      Finance
    • MetLife Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - METLIFE INC (0001099219) (Filer)

      4/30/25 4:33:08 PM ET
      $MET
      Life Insurance
      Finance

    $MET
    Financials

    Live finance-specific insights

    See more
    • MetLife Announces 1Q 2025 Results

      MetLife, Inc. (NYSE:MET) today announced its first quarter 2025 results. Earnings Per Share   Return on Equity (ROE) 1Q 2025   1Q 2025 Net Income $ 1.28   ROE 14.9 % Adjusted Earnings $ 1.96   Adjusted ROE 14.4 % Net income increased 10% to $879 million. Premiums, fees and other revenues (PFOs) increased 14% to $13.6 billion. Adjusted earnings rose 1% to $1.3 billion. Higher life underwriting margins, volume growth and variable investment income were partially offset by unfavorable foreign currency impacts and lower recurring interest margins. Book value increased 2% to $35.16 per share. A

      4/30/25 4:15:00 PM ET
      $MET
      Life Insurance
      Finance
    • MetLife CFO John McCallion Provides First Quarter 2025 Financial Update Video

      MetLife, Inc. (NYSE:MET) today announced that John McCallion, executive vice president and CFO, and head of MetLife Investment Management, has provided a first quarter 2025 financial update video. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430216095/en/ The video can be viewed on the company's website at https://www.metlife.com/about-us/newsroom/#video. About MetLife MetLife, Inc. (NYSE:MET), through its subsidiaries and affiliates ("MetLife"), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers b

      4/30/25 4:15:00 PM ET
      $MET
      Life Insurance
      Finance
    • MetLife Announces New $3 Billion Share Repurchase Authorization

      MetLife, Inc. (NYSE:MET) today announced that its board of directors has approved a new $3 billion authorization for the company to repurchase its common stock. The new authorization is incremental to the approximately $360 million remaining under the company's prior authorization announced in May 2024. "This new share repurchase authorization and the 4.1% increase in our common stock dividend that we announced earlier this month reflect MetLife's financial strength and all-weather performance," said MetLife President and Chief Executive Officer Michel Khalaf. "Altogether, these actions illustrate our commitment to providing an attractive total return for our shareholders as part of our Ne

      4/30/25 4:14:00 PM ET
      $MET
      Life Insurance
      Finance

    $MET
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MET
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MET
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Johnson Jeh C. bought $879 worth of shares (17 units at $51.69) and was granted 19 shares, increasing direct ownership by 1% to 2,545 units (SEC Form 4)

      4 - METLIFE INC (0001099219) (Issuer)

      12/18/23 5:20:05 PM ET
      $MET
      Life Insurance
      Finance
    • Director Mumenthaler Christian Stephane was granted 353 units of Common Stock (SEC Form 4)

      4 - METLIFE INC (0001099219) (Issuer)

      5/5/25 4:03:34 PM ET
      $MET
      Life Insurance
      Finance
    • New insider Mumenthaler Christian Stephane claimed no ownership of stock in the company (SEC Form 3)

      3 - METLIFE INC (0001099219) (Issuer)

      5/2/25 11:22:03 AM ET
      $MET
      Life Insurance
      Finance
    • Director Johnson Jeh C. was granted 540 shares, increasing direct ownership by 10% to 6,183 units (SEC Form 4)

      4 - METLIFE INC (0001099219) (Issuer)

      4/3/25 4:29:21 PM ET
      $MET
      Life Insurance
      Finance
    • MetLife Investment Management Originates $21.6 Billion in Private Credit Transactions in 2024

      MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE:MET), today announced that it originated $21.6 billion in private credit transactions in 2024. MIM's private credit assets under management stood at $129.1 billion as of December 31, 2024.1 MIM's origination was well diversified across the private credit platform with: $6.8 billion in residential credit $6.4 billion in corporate debt $5.6 billion in infrastructure debt $2.8 billion in asset-based finance transactions. "MIM is a premier originator of private assets and our clients appreciate the quality and diversity of transactions that we participate in on their behalf," said

      5/7/25 8:30:00 AM ET
      $MET
      Life Insurance
      Finance
    • MetLife and Aura Introduce New Category of AI-Powered Tools to U.S. Employer Benefits Channel to Take on the Mental Health Crisis

      Leading Benefits Provider Committed to Meeting the Needs of Today's Workforce with Tools to Promote Mental Wellbeing and Balance for Employees and Families MetLife, a market-leading benefits provider, and their exclusive partner Aura, today announced an entirely new category of online protections for employers and their workforces nationwide, which complement their traditional Identity and Fraud Protection offering. These first-of-their-kind, AI-based tools are designed to empower employees to protect their families from the mental health and physical harm of the online world. The magnitude of the issue for an entire generation of children is stark. Today, 40% of high school students expe

      5/6/25 9:00:00 AM ET
      $MET
      Life Insurance
      Finance
    • MetLife Investment Management Announces Driscoll Retirement

      Funk Named Interim President MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE:MET), today announced that after a distinguished career spanning decades in the asset management industry, including eight years at MIM, Jude Driscoll will be retiring from the company, effective May 2. Brian Funk has been appointed as MIM's interim president. Throughout his tenure, Driscoll played a critical role in advancing MIM's strategic priorities, building relationships and driving strong results for clients. "On behalf of the entire MIM team, I want to thank Jude for his leadership and contributions and wish him all the best in retirement," said John

      5/2/25 8:30:00 AM ET
      $MET
      Life Insurance
      Finance